Anzeige
Mehr »
Montag, 16.06.2025 - Börsentäglich über 12.000 News
Von SOL zu BTC: Pioneer aktiviert automatisierte Bitcoin-Treasury über Kora AI Beta
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJAY | ISIN: US19240Q2012 | Ticker-Symbol:
NASDAQ
13.06.25 | 21:59
7,090 US-Dollar
-1,80 % -0,130
1-Jahres-Chart
COGENT BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
COGENT BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur COGENT BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiCogent Biosciences, Inc.: Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing1
05.06.Cogent Biosciences, Inc. - 8-K, Current Report-
06.05.Cogent Biosciences, Inc. - 10-Q, Quarterly Report1
06.05.Cogent Biosciences, Inc. - 8-K, Current Report1
06.05.Cogent Biosciences reports Q1 results2
25.04.Cogent Biosciences, Inc.: Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders3
25.03.Cogent Biosciences, Inc.: Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting2
COGENT BIOSCIENCES Aktie jetzt für 0€ handeln
25.02.Cogent Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
25.02.Cogent Biosciences, Inc. - 10-K, Annual Report-
25.02.Cogent Biosciences, Inc. - 8-K, Current Report-
10.02.Cogent Biosciences, Inc.: Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting2
16.01.Hedge Fund and Insider Trading News: Bill Ackman, Scott Bessent, Alden Global Capital, Saba Capital, Point72 Asset Management, Citadel Investment Group, Cogent Biosciences Inc (COGT), Immunovant Inc (IMVT), and More4
13.01.Cogent Biosciences sets key 2025 milestones for drug trials1
13.01.Cogent Biosciences legt wichtige Meilensteine für Medikamentenstudien bis 2025 fest2
09.12.24Cogent Biosciences, Inc.: Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients35856% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS 89% of patients had >50% decrease in serum tryptase by...
► Artikel lesen
08.12.24Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)25152% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with...
► Artikel lesen
06.08.24Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results449SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 2Q 2024 with $390 million, sufficient to fund...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1